Linear immunoglobulin A bullous dermatosis induced by atezolizumab
https://doi.org/10.4081/dr.2024.9923
HTML: 15
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Linear immunoglobulin A bullous dermatosis (LABD) is a rare immune-mediated vesiculobullous disease that is reported to be induced by infections or medications. Atezolizumab is a monoclonal antibody that targets programmed cell death ligand-1 and has been used to treat multiple cancers. Here, we report a case of drug induced LABD following the administration of atezolizumab.
Bernett CN, Fong M, Yadlapati S, Rosario-Collazo JA. Linear IgA dermatosis. Treasure Island (FL): StatPearls Publishing; 2022.
Lammer J, Hein R, Roenneberg S, et al. Drug-induced linear IgA bullous dermatosis: a case report and review of the literature. Acta Dermatol Venereol 2019;99:508-15.
Sibaud V, Meyer N, Lamant L, et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016;28:254-63.
Aguilar‐Duran S, Mee J, Popat S, Heelan K. Atezolizumab‐induced linear IgA bullous dermatosis. Br J Dermatol 2022;187:e193.
Yawalkar N, Reimers A, Hari Y, et al. Drug-induced linear IgA bullous dermatosis associated with ceftriaxone-and metronidazole-specific T cells. Dermatology 1999;199:25-30.
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
